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Abstract
Background: Apert syndrome is characterized by craniosynostosis and limb abnormalities and is primarily caused
by FGFR2 +/P253R and +/S252W mutations. The former mutation is present in approximately one third whereas
the latter mutation is present in two-thirds of the patients with this condition. We previously reported an inbred
transgenic mouse model with the Fgfr2 +/S252W mutation on the C57BL/6J background for Apert syndrome. Here
we present a mouse model for the Fgfr2+/P253R mutation.
Results: We generated inbred Fgfr2
+/P253R mice on the same C56BL/6J genetic background and analyzed their
skeletal abnormalities. 3D micro-CT scans of the skulls of the Fgfr2
+/P253R mice revealed that the skull length was
shortened with the length of the anterior cranial base significantly shorter than that of the Fgfr2
+/S252W mice at P0.
The Fgfr2
+/P253R mice presented with synostosis of the coronal suture and proximate fronts with disorganized
cellularity in sagittal and lambdoid sutures. Abnormal osteogenesis and proliferation were observed at the
developing coronal suture and long bones of the Fgfr2
+/P253R mice as in the Fgfr2
+/S252W mice. Activation of
mitogen-activated protein kinases (MAPK) was observed in the Fgfr2
+/P253R neurocranium with an increase in
phosphorylated p38 as well as ERK1/2, whereas phosphorylated AKT and PKCa were not obviously changed as
compared to those of wild-type controls. There were localized phenotypic and molecular variations among
individual embryos with different mutations and among those with the same mutation.
Conclusions: Our in vivo studies demonstrated that the Fgfr2 +/P253R mutation resulted in mice with cranial
features that resemble those of the Fgfr2
+/S252W mice and human Apert syndrome. Activated p38 in addition to the
ERK1/2 signaling pathways may mediate the mutant neurocranial phenotype. Though Apert syndrome is
traditionally thought to be a consistent phenotype, our results suggest localized and regional variations in the
phenotypes that characterize Apert syndrome.
Background
Fibroblast growth factor receptor 2 (FGFR2) belongs to
a receptor tyrosine kinase family which is comprised of
four members, FGFR1-4. The FGFR protein structure is
composed of three extracellular immunoglobulin-like
domains, a hydrophobic transmembrane, and a cytoplas-
mic tyrosine kinase domain [1]. The second and third
immunoglobulin-like domains are the primary binding
sites for ligands, fibroblast growth factors (FGFs), and
heparin [2,3]. There are 22 known FGFs that bind to
the FGFRs to control the balance among migration,
proliferation, differentiation, and survival of a wide vari-
ety of cells [3,4]. Normally, mesenchymal ligands FGF7
and FGF10 activate the FGFR2 IIIb isoform, whereas
epithelial FGFs -2, -4, -6, -8, and -9 activate the FGFR2
IIIc isoform [5-7].
FGF binding to FGFR stimulates receptor dimeriza-
tion, tyrosine phosphorylation, and activation of signal
transduction pathways. Activities of mitogen-activated
protein kinases (MAPK) p38, ERK1/2, PI3 kinase-AKT
pathway, PLCg pathway and other pathways vary
depending on the cell type [4,8,9]. P38 as well as ERK1/
2 play an important role in osteoblast differentiation
[10-12]. Raucci showed that AKT activation correlates
with osteoblast differentiation. ERK1/2 and AKT have
distinct effects in FGF-induced osteoblast proliferation
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FGF-induced proliferation and differentiation, while
AKT is important for osteoblast survival [13]. It was
also found that the PKC pathway mediates proliferation,
differentiation, as well as cell-cell adhesion among
osteoblasts [14,15].
Ossification of the majority of neurocranial sutures is
an intramembranous process. The two major midline
sutures in mice are the interfrontal (corresponding to
the human metopic suture) between the frontal bones
and the sagittal between the parietal bones. The two
major transverse sutures include the coronal sutures
between the frontal and parietal bones and the lambdoid
sutures between the parietal and the interparietal (corre-
sponding to the human squamous occipital) bones.
These sutures have different tissue origins because the
frontal bones are neural crest-derived and the parietal
bones are mesoderm-derived with a tongue of neural
crest between the two parietal bones [16]. The normal
growth and morphogenesis of calvarial sutures is depen-
dent upon a balance between proliferation of osteogenic
precursors within the sutural mesenchyme and differen-
tiation to osteoblasts at the osteogenic fronts [17,18].
Ossification of most of thec r a n i a lb a s ea n dt h el o n g
bones is an endochondral process. Mesenchymal cells dif-
ferentiate into chondrocytes to form a cartilaginous tem-
plate, which is replaced by osteoblast differentiation and
bone formation [19]. The mouse cranial base consists of
several bones including the presphenoid, basisphenoid,
basioccipital, the ethmoid and the tympanic bullae of the
temporal bones. The basioccipital and petrous portion of
the temporal bones lack a neural crest contribution and
are derived from mesoderm [20,21]. During both osteo-
genesis and chondrogenesis, FGF/FGFR signaling regulates
cell proliferation and differentiation [17,22,23].
In humans, Apert syndrome is caused by gain of func-
tion mutations of FGFR2. Apert syndrome [MIM
#101200] is a congenital condition characterized by cra-
niosynostosis involving the premature fusion of one or
more cranial sutures, midfacial hypoplasia and syndac-
tyly of hands and feet. Among the calvarial sutures
affected in the Apert syndrome patients, the coronal
suture is most commonly involved [24]. Almost all cases
o fA p e r ts y n d r o m ea r ed u et oo n eo ft w om u t a t i o n s ,
each an amino acid substitution in adjacent residues,
Ser252Trp (S252W) and Pro253Arg (P253R) of FGFR2
[25,26]. Both mutations affect the highly conserved lin-
ker region between the immunoglobulin-like II and III
domains and result in increased affinity and altered spe-
cificity of FGF ligand binding [27-29]. In vivo and in
vitro studies of fetal and postnatal sutural cells from
Apert patients with craniosynostosis and either mutation
demonstrated perturbations of proliferation, differentia-
tion, and/or apoptosis [30-32].
Two mouse models of Apert syndrome containing the
Fgfr2 +/S252W mutation, one outbred [33] and one
inbred [34], and one outbred mouse model containing
the Fgfr2+/P253R mutation [35] have been reported.
These mutant mice showed skull malformations with
premature closure of sutures associated with abnormal
osteogenic proliferation, differentiation and/or cell apop-
tosis. Their skull base and long bones showed growth
retardation with abnormal proliferating and/or hyper-
trophic zone(s). The FGF/FGFR2 signaling pathway was
studied in the outbred Apert mouse models [33,35,36].
Shukla et al. showed that phosphorylation of
ERK1/2 was higher in lung, thymus, kidney and liver in
Fgfr2
+/S252W mice compared to wild-type controls, but
the craniofacial tissues were not examined [37]. Holmes
et al. found increased phosphorylation of AKT and p38
in newborn Fgfr2
+/S252W calvarial tissues and/or immor-
talized cells [36]. In Fgfr2
+/P253R mice, Yin et al. checked
signaling by cell culture in bone marrow cells derived
from femoral bones with endochondral ossification, and
found enhanced expression levels of phosphorylated
ERK1/2, but no signaling data are reported for the neu-
rocranium in this mouse [35].
To identify the skeletal malformations and related
intracellular signaling caused by the Fgfr2 +/P253R
mutation, we studied the molecular signaling in the
skull of our independently generated, inbred Fgfr2
+/P253R
mouse with the same C57BL/6J genetic background as
our previously reported Fgfr2
+/S252W mouse [34]. The
production of the inbred Fgfr2
+/P253R mouse enables
direct comparison between models carrying dissimilar
Fgfr2 mutations but on similar backgrounds without the
confounding influence of uncommon background genes.
Gross and histological abnormalities of the neurocra-
nium, skull base and long bones were analyzed in our
Fgfr2
+/P253R mice and found to be similar to those of
our Fgfr2
+/S252W mutant mice. Furthermore we found
the activation of p38 and ERK1/2 signaling occurred in
the neurocranium of the Fgfr2
+/P253R mouse.
Results
Generation and characterization of Fgfr2
+/P253R
mutant mice
We designed a gene targeting construct to site-specifi-
cally knock-in the Fgfr2 758C>G mutation (protein
change P253R) into the mouse genome by homologous
recombination (see additional file 1). Southern blot
hybridization, PCR, and sequencing confirmed the pre-
dicted mutant allele. An inbred line was generated by
mating our heterozygote Fgfr2
+/P253Rneo mice with
C57BL/6J mice for more thant e ng e n e r a t i o n s .T h e
inserted neo cassette was found by RT-PCR to decrease
dramatically the expression of the mutant allele (see
additional file 2). We then excised the floxed neo
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+/P253Rneo mice
with EIIA-Cre transgenic mice that were also generated
on a B6 genetic background. Heterozygous Fgfr2
+/P253R
mice were born at the expected frequency of 50%, and
their mutant and wild-type alleles resulted in similar
Fgfr2 mRNA and protein expression levels (see addi-
tional file 2). The Fgfr2 P253R allele was expressed in
multiple organs including the skull, limb, and other tis-
sues (i.e., brain, lung, skin, heart, liver, stomach, intes-
tine, and spleen; data not shown).
At postnatal stages P0 and P10 the mutants could be
distinguished from their littermate controls by their
domed shaped head, which had a decreased anteropos-
terior (or rostro-caudal) length (Figure 1a-d and see
additional file 2). The body size and weight of the
mutants were similar to the controls at P0 (+/P253R [n
= 43] versus +/+ [n = 50]: 1.326 ± 0.080 g versus 1.361
± 0.112 g, P = 0.0935). However, with age the mutants
had poor growth and became increasingly different from
their littermate controls (see additional file 2). The body
weight of mutants became significantly less than that of
control littermates with increasing age (see additional
file 2; e.g., at P5, +/P253R [n = 9] versus +/+ [n = 10]:
2.089 ± 0.446 g versus 3.530 ± 0.302 g, P < 0.0001).
Almost half of the Fgfr2
+/P253R mutants died within 24-
36 hours after birth; most died within 2 weeks of age
(see additional file 2), and very few survived to 3 weeks.
Skeletal abnormalities in Fgfr2
+/P253R mutant mice
Necropsy of P0 Fgfr2
+/P253R mice revealed multiple mal-
formations of the skeleton system including skull, palate,
sternum, and long bones (+/P253R [n = 10] versus +/+
[n = 10]). At P10, the Fgfr2
+/P253R skull was consistently
smaller than that of littermate controls (Figure 1a-d)
and the coronal suture was often prematurely fused at
P0 (Figure 2a-d). From E15.5 until P0, all mutants
(+/P253R [n = 22] versus +/+ [n = 22]) exhibited bilat-
eral incomplete fusion at the junction of the primary
and secondary palatal shelves (Figure 1e-h). All mutants
at P0 had abnormal bony fusion of the sternum (Figure
1i, j). At P0, the lengths of the humerus, radius, femur,
and tibia were similar between mutant and wild-type,
but later at P10, they became relatively shorter in the
mutant (see additional file 2).
Figure 1 Abnormal gross appearance and histology of Fgfr2
+/P253R mice. A-D) Alizarin red S and Alcian blue staining of the skull shows
domed-shaped skulls with shortened anterioposterior length, short nasal snouts and upper jaw in mutant; I, J) Alizarin red S and Alcian blue
staining of the chest shows abnormal bony fusion of sternum (white arrow) in mutant. E-H) Palate abnormalities: (E, F) Superior view shows a
defect located at the junction between the primary and secondary palate in mutant (arrow). (G, H) Histology shows incomplete fusion in mutant
(arrows). (K, L) Abnormal chondro-osseous transition at the physis in mutant (brackets). Panels A, C, E, G, I, and K are from littermate controls.
Panels B, D, F, H, J, and L are the corresponding organs and tissues in mutant mice. (Scale bars: I-P = 50 μm).
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Page 3 of 20Figure 2 Micro-CT of the skulls of Fgfr2
+/P253R mice and wild-type littermates. A-D) Mutant skull is shorter in the rostro-caudal, maxilla, and
mandible lengths than those of the wild-type controls. In the mutants, the zygomatic process of the maxilla and the malar bone are fused (B, D;
white arrows) and unilateral or bilateral coronal synostosis occurs (B, D; black arrows). E, F) The developing mutant palates are shorter than the
wild-type. In the mutants, the inter-premaxillary suture is patent (F; white arrow) with fusion of the premaxilla-maxillary sutures (F; black arrow).
The suture between the horizontal plate of the palatine bone and palatal process of the maxilla is patent in Fgfr2
+/P253R and wild-type (F; red
arrow) but partially fused in Fgfr2
+/S252W mice (not shown). The midline suture between the palatal shelves of the maxilla are patent in mutant
mice as well as in some controls (F; blue arrow). Portions of the maxilla were darkened in Photoshop to allow observation of the fusion of the
zygomatic process. Panels A, C, and E are from littermate controls. Panels B, D, and F are from Fgfr2
+/P253R mice.
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+/P253R mice
compared to those of Fgfr2
+/S252W mice
We obtained high resolution micro-CT (HRCT) scans of
skulls from our inbred Fgfr2
+/P253R and Fgfr2
+/S252W
mice and their littermate controls at P0. The 3D coordi-
nates of specific craniofacial landmarks http://www.geta-
head.psu.edu/LandmarkNewVersion/P0mouseskull_up-
dated_applet.html were recorded and used in Euclidean
distance matrix analysis of landmark data. We tested for
morphological differences of specific craniofacial fea-
tures in each mutant group as compared to its litter-
mate controls and we tested for differences in the
magnitude of mutant to control contrasts between the
two mouse models for Apert syndrome. Statistical sig-
nificance of the differences was determined by using
nonparametric confidence intervals [38].
Our statistical analyses showed that both Fgfr2 muta-
tions caused similar craniofacial effects at P0 (Table 1).
Both Fgfr2
+/P253R and Fgfr2
+/S252W skulls were signifi-
cantly smaller than those of wild-type littermates as
measured along the rostro-caudal axis (skull length) and
the mediolateral axis at the zygomatic process of the
temporal bones (facial width). The skull lengths, mea-
sured from the most anterior aspect of the muzzle to
points on the occipital bone at the caudal end of the
skull, were reduced by 4-5% in both models (Figure 2a,
b; Figure 3). Intercanthal distances were reduced by 4-
5% in both mutant mice. Skulls of mutant and wild-type
mice did not differ significantly in width at more poster-
ior locations on the neurocranium, specifically the
distance between the left and right squamosal bones.
Skull height was increased relative to littermate controls
by 3-4% in both mutants (Figure 2c, d; Figure 3).
Other localized measurements showed significant dif-
ferences in the effects of the Fgfr2 +/P253R and
+/S252W mutations (significant by confidence interval
testing, a =0 . 1 0 ;T a b l e1a n dF i g u r e3 ) .T h em a x i l l a
was more reduced relative to the mandible in both
mutant mice, but the Fgfr2
+/P253R mice showed signifi-
cantly less reduction in the maxilla compared to Fgfr2
+/S252W mice. The Fgfr2
+/P253R maxilla was reduced by
10% (Figure 2c, d) and the Fgfr2
+/S252W maxilla was
reduced by 13%. The mandibles of both mutant mice
were reduced relative to littermate controls by approxi-
mately 5%. Total palatal length of the Fgfr2
+/P253R mice
was reduced by 4% relative to littermate controls (Figure
2e, f), whereas it was reduced by 8% in Fgfr2
+/S252W
mice. The more posterior portion of the palate (mea-
s u r e df r o mt h ep o s t e r i o ra s p e c to ft h ep a l a t a lf o r a m e n
to the posterior nasal spine) was not obviously affected
in the Fgfr2
+/P253R mouse, but was reduced by 7% in the
Fgfr2
+/S252W model when compared to controls.
In contrast, the length of nasal region in Fgfr2
+/P253R
mice was significantly reduced by 10%, while it was
reduced by 4% in Fgfr2
+/S252W mice relative to littermate
controls. The nasal reduction in Fgfr2
+/P253R mice was
consistent with observations by Yin et al. [35]. Further-
more, the Fgfr2
+/P253R mice were significantly different
from their littermate controls for the anterior and over-
all length of the cranial base; whereas the Fgfr2
+/S252W
Table 1 Skull measurements in Apert syndrome mice and littermate controls
Measurements
Landmarks +/P253R
(n = 10)
+/+ littermate
(n = 4)
+/S252W (n = 7) +/+ littermate
(n = 11)
Skull length (rnsla – rocc)
1 9.29 mm
a 9.77 mm 9.42 mm*
a 9.83 mm
Skull height (lpto-bas)
1 4.78
a 4.65 4.91
a 4.70
Neurocranial width at squamosal bone (lpsq-rpsq)
1 6.31 6.34 6.51* 6.46
Intercanthal distance (lflac-rflac)
1 3.67
a 3.85 3.83
a 3.95
Facial width at zygomatic process of temporal bone (lzyt-rzyt)
1 5.81 6.00 6.04
a 6.11
Maxilla length (laalf-lptyp)
1 ** 4.27
a 4.73 4.24
a 4.81
Mandible length (mlsin-mlang)
1 4.31
a 4.53 4.47
a 4.69
Maxilla/mandible ratio 0.99 1.04 0.95 1.03
Palate length (laalf-lpns)
1 ** 3.36
a 3.48 3.24
a 3.50
Length of nasal region (lnsla-lflac)*** 2.50
a 2.79 2.64
a 2.74
Overall cranial base length (amsph-bas) 3.09
a 3.19 3.25 3.28
Anterior cranial base length*** (amsph-lsyn) 1.60
a 1.68 1.68 1.69
Posterior cranial base length (lsyn-bas) 1.66 1.70 1.78 1.77
aThe models were significantly different from their control littermates for these linear distances
* Measures come from a sample size of 4.
** Contrasts between mutants and their control littermates indicated that Fgfr2
+/P253R were significantly less affected than Fgfr2
+/S252W
*** Contrasts between models and their control littermates indicated that Fgfr2
+/P253R were significantly more affected than Fgfr2
+/S252W
1http://www.getahead.psu.edu for precise landmark definitions.
(Ref. [38] Richtsmeier and Lele, 1993; Ref. [47] Lele and Richtsmeier, 2001)
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in the overall, anterior or posterior cranial base lengths
(Table 1 and Figure 3). When directly comparing the
Fgfr2
+/P253R to the Fgfr2
+/S252W mice, only the anterior
cranial base length was significantly different. We did
not observe premature fusion of the intrasphenoidal and
spheno-occipital synchondroses in either mutant at P0.
HRCT images revealed similar patterns of calvarial
suture fusion in Fgfr2
+/P253R and Fgfr2
+/S252W mice.
Coronal synostosis was present in most P0 mutant mice,
whereas these sutures were patent in littermate controls
(Figure 2a-d and Table 2). Both mutant mice revealed
premature closure of the suture between the zygomatic
process of the maxilla and the zygomatic bones, and the
premaxillary-maxillary sutures (Figure 2a-d and Table
2). In contrast, the inter-premaxillary suture appeared
patent in mutant mice, while it was closed in controls
(Figure 2e, f), an observation consistent with our gross
Figure 3 Morphometric analyses of the skulls of Fgfr2
+/P253R and Fgfr2
+/S252W mice. EDMA results from intra-model comparisons between
mutant and normal littermates (for further details see Table 1). From top to bottom: superior, lateral and inferior views of micro-CT 3D
reconstructions of the skull of a Fgfr2
+/P253R mouse on the left, and of a Fgfr2
+/S252W mouse on the right. Red lines indicate linear distances that
are significantly shorter in both mutants in comparison with their littermate controls; blue lines represent linear distances that are significantly
longer in mutants in comparison to their littermate controls; and green lines show linear distances that are similar in mutants and littermate
controls (i.e. no statistical significant differences at the a = 0.1 level).
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suture between the horizontal plates of the palatine
bones was patent in all mutant mice in both models
while it was closed in some of their respective controls.
T h es u t u r eb e t w e e nt h eh o r i z o n t a lp l a t eo ft h ep a l a t i n e
bone and the palatal shelf of the maxilla was patent in
nine of the ten Fgfr2
+/P253R mice and in three of the
seven littermate controls. This ratio of patent to closed
sutures in the mutant and controls were different for
the Fgfr2
+/S252W mice, which had only one patent in
eight mutants and in seven of the twelve littermate con-
trols (Table 2).
Neurocranial sutural dysmorphology in Fgfr2
+/P253R
mutant mice
Sutures were examined microscopically to further char-
acterize the abnormalities observed in the mutant skulls
at different developmental stages. Coronal sutures
exhibited presynostosis or synostosis at P0 (Figure 4)
similar to the Fgfr2
+/S252W mice [34]. We analyzed the
coronal suture in detail because synostosis of this suture
is most characteristic of human Apert syndrome. In the
Fgfr2
+/P253R coronal sutures at P0, there was presynosto-
sis defined here as a more proximate location of the
osteogenic fronts with disorganized cellularity and the
initiation of osteoid deposition. In the littermate con-
t r o l s ,t h eo s t e o g e n i cf r o n t sw e r ew e l lo r g a n i z e dw i t ha
clear separation between the frontal and parietal bones
(Figure 4a, b; P0 +/P253R [n = 12] versus +/+ [n = 13]).
By the later stages P5 (Figure 4c, d; +/P253R [n = 3]
versus +/+ [n = 3]) and P10( + / P 2 5 3 R[ n=3 ]v e r s u s
+/+ [n = 3]), the osteogenic fronts in the mutants fused
together with the formation of osteoid, but the fronts
still were separated in the controls. The transverse
lambdoid and midline sagittal sutures in mutants at P0
also showed proximate osteogenic fronts with increased
cellularity and osteoid deposition, while the controls had
separated osteogenic fronts (Figure 4e, f, lambdoid
suture; Figure 4g, h, sagittal suture). Also similar to
what we reported in Fgfr2
+/S252W mice [34], there was
ectopic cartilage at the sagittal suture in Fgfr2
+/P253R
mice from E16.5 to P0 (Figure 4i, j; +/P253R [n = 6]
versus +/+ [n = 21]). In all mutants, but only in two of
the 21 controls at P0, cartilage was observed at the junc-
tion between the parietal and interparietal bone.
Abnormal osteoblastic proliferation, differentiation and
no increased apoptosis at the coronal sutures in
Fgfr2
+/P253R mutant mice
The effects of the Fgfr2 +/P253R mutation on prolifera-
tion, differentiation and apoptosis were investigated at
the coronal suture from E17.5 to P5 as the involvement
of these processes varied during development. Cell pro-
liferation was analyzed by calculating the ratios of the
number of BrdU positive cells to total cells between and
including the osteogenic fronts in mutants and litter-
mate controls. At E17.5 the ratio was obviously
decreased in mutants as compared to controls (+/P253R
[n = 6] versus +/+ [n = 6]: 0.2 ± 0.0 versus 0.4 ± 0.1,
P = 0.0022) (Figure 5a, b). While at later stages E19
(+/P253R [n = 4] versus +/+ [n = 4]) and P5 (+/P253R
[n = 4] versus +/+ [n = 4]), there was no difference in
the proliferation between the mutants and controls (P =
0.4800 and P = 0.0900, respectively; data not shown).
Differentiation local to the coronal suture was studied
from E17.5 to P5 by using alkaline phosphatase (ALP),
Runx2, osteopontin, osteonectin, collagen type I, and
osteocalcin markers. Apparent differences in the expres-
sion of these markers were found between mutants and
controls. In controls, the coronal suture was present as
a layer of undifferentiated cells without ALP expression
located between the frontal and parietal bones; whereas
in mutants, this layer exhibited a cellular disorganiza-
tion with expanded and broader ALP expression (Figure
5c, d). There was also increased staining of Runx2 in
mutant coronal sutures compared to wild-type (Figure
5e, f). Enhanced expression of early osteoblast markers
ALP and Runx2 demonstrated increased osteoblast dif-
ferentiation along the overlapping osteogenic fronts of
Fgfr2
+/P253R mice compared with littermate controls. In
Table 2 Suture closure in Apert syndrome mice
Fusion
Sutures +/P253R
(n = 10)
+/+ littermate
(n = 7)
+/S252W
(n = 8)
+/+ littermate
(n = 12)
closed/total* closed/total closed/total patent/closed
Coronal (bi- or unicoronal) 9/10 0/7 7/8 0/12
Zygomatic-maxillary 10/10 0/7 7/8 0/12
Maxilla-premaxillary 10/10 0/7 8/8 0/12
Inter-premaxillary 0/10 7/7 1/8 11/12
Inter-palatine 0/10 2/7 0/8 3/12
Maxillary-palatine 1/10 4/7 7/8 5/12
* The observation of “closed” varies from simple bridging across the suture to complete closure. Closure can be unilateral or bilateral. Because these are P0 mice,
it should be recognized that suture closure is a dynamic process and will vary given the age of the mice observed.
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Page 7 of 20Figure 4 Histological analysis of the abnormal calvarial sutures in Fgfr2
+/P253R mice. A-D) HE staining shows the abnormal development of
the mutant coronal suture from P0 to P5 with presynostosis, disorganization of cells between the osteogenic fronts and osteoid deposition at P0
(A, B); and synostosis at P5 (C, D). E-H) HE staining shows the abnormal development of the mutant lambdoid (E, F) and sagittal suture (G, H)
with proximate osteogenic fronts and cellular disorganization at P0. I, J) abnormal cartilage at the sagittal suture (blue arrows). Panels A, C, E, G
and I are from littermate controls. Panels B, D, F, H and J are the corresponding regions in mutant mice. Black arrows, osteogenic fronts;
arrowheads, presynostosis/synostosis. (Scale bars: A-D = 25 μm; E-J = 50 μm).
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Page 8 of 20Figure 5 Abnormal proliferation, differentiation and no obvious change in apoptosis at the coronal suture in Fgfr2
+/P253R mice. A, B)
Immunohistochemical staining of BrdU shows decreased numbers and abnormal distribution of positive cells in mutants at E17.5 (arrow). C, D)
ALP staining showed broad ALP domain and expansion of expression into the coronal suture of the mutants at E17.5 (arrow). E, F)
Immunohistochemical staining of Runx2 shows increased expression and abnormal differentiation at the osteogenic fronts at E17.5 (arrow). G, H)
In situ hybridization of osteonectin shows accelebrated bone formation in mutants at E17.5. I, J) TUNEL staining shows no clear difference in
apoptosis between the mutant and wild-type at P5 (arrows). Panels A, C, E, G and I are from littermate controls. Panels B, D, F, H and J are the
corresponding regions in mutant mice. (Scale bars: A-F = 50 μm).
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showed a similar expression pattern in both mutant and
wild-type in cells flanking the developing bone of the
sutures. However in the mutant, bone growth pro-
gressed further with more overlap of the frontal and
parietal bones (Figure 5g, h expression of osteonectin;
data of other markers not shown). These results indi-
cated increased osteogenic differentiation as well as
accelerated bone growth in Fgfr2
+/P253R mice sutures.
Apoptosis at the coronal suture was studied by TUNEL
staining. There was no apparent difference in apoptosis
between mutants and controls at E17.5, P0, and P5 (Fig-
ure 5i, j).
BrdU, osteogenic markers and TUNEL staining were
also performed on the coronal suture of the Fgfr2
+/S252W
mice from E17.5 to P0 and yielded similar results to
those found for the Fgfr2
+/P253R mice. The ratio of BrdU
positive cells to total cells were significantly decreased
in Fgfr2
+/S252W mice compared to wild-type littermates
(E17.5 +/S252W [n = 6] versus +/+ [n = 6]: 0.2 ± 0.1
versus 0.4 ± 0.0, P = 0.0022) (see additional file 3).
Osteogenic markers showed increased differentiation
and accelerated bone formation (see additional file 3,
expression of ALP and osteonectin; data of other mar-
kers not shown). There was no apparent difference in
apoptosis between Fgfr2
+/S252W mice and controls at P0
(see additional file 3).
Limb shortening with abnormal osteogenic differentiation
in Fgfr2
+/P253R mutant mice
The forelimbs and hindlimbs showed decreased postna-
tal growth in the Fgfr2
+/P253R mice as compared to litter-
mate controls. By P12, the lengths of the limbs of
mutants were significantly smaller, but relatively propor-
tional as compared to controls (+/P253R [n = 3] versus
+/+ [n = 3]). For the humerus and femur, the lengths of
the mutants were 7.964 ± 0.094 and 8.580 ± 0.078 mm,
while that of the controls were 9.356 ± 0.133 and 10.720
± 0.240 mm, respectively (for both humerus and femur,
P = 0.007). For the radius or ulna and tibia or fibula,
the lengths of the mutants were 9.443 ± 0.195 and
11.068 ± 0.382 mm, while those of the controls were
11.139 ± 0.147 and 13.494 ± 0.044 mm, respectively (P
= 0.010 and P = 0.012). The ratios of the humerus to
the radius or ulna (forelimb) as well as the ratios of the
femur to the tibia or fibula (hindlimb) were not signifi-
cantly different (P =0 . 8 6 6a n dP = 0.396, respectively).
None of the mutants exhibited syndactyly (+/P253R
[n = 52] versus +/+ [n = 58]). Our previous report of
Fgfr2
+/S252W mice also showed that although the mutant
mice were smaller than control littermates, the forelimb
and hindlimb lengths were proportional in mutant and
no syndactyly was detected [34].
From E17.5 to later stages such as P10, histopathol-
ogy of the long bones revealed mild abnormalities at
the physis with the hypertrophic zone most affected as
it appeared disorganized in Fgfr2
+/P253R mice (Figure
1k, l). Increased numbers of BrdU positive cells at the
chondro-osseous junction and the metaphysis revealed
abnormal osteoblast proliferation (Figure 6a, b). In
situ hybridization of osteogenic markers showed
increased expression in preosteoblasts or osteoblasts
in the same region, suggesting increased osteoblast
differentiation (Figure 6c-f). For Fgfr2
+/S252W mice we
obtained similar results (see additional file 4). Because
the abnormalities of the limbs were less striking than
those of the skull, we focused our further molecular
studies on the skull.
Abnormal molecular signaling in the skull of Fgfr2
+/P253R
mutant mice
To investigate the molecular basis or signaling of the
abnormal proliferation and differentiation observed in
the skulls of Fgfr2
+/P253R mutant mice at E17.5, we
checked the phosphorylated and total protein levels of
MAPK ERK1/2, p38, PKCa and AKT in tissues isolated
from the neurocranium and cranial base of embryos
from at least 3 litters by western blot analysis. The
phosphorylated and total protein expression levels were
normalized to b-actin levels, then the relative ratio of
phosphorylated protein/total protein (phospho/total)
between the mutant and wild-type control was calcu-
lated for the above markers. Although there was in vivo
variation in the level of phosphorylation of mitogen-acti-
vated protein kinases (MAPK) in the neurocranium of
inbred Fgfr2
+/P253R embryos, the results showed that the
median phosphorylated ERK1/2 and p38 levels were
increased, but by less than 1.5 fold (Figure 7a, b, e).
These MAP kinases were slightly increased in the cra-
nial base of the Fgfr2+/P253R mutants based on the
median value, but some individuals showed evident
increase (Figure 8a, b, e). Phosphorylated PKCa and
AKT protein levels did not show an obvious increase in
either the neurocranium and skull base of Fgfr2
+/P253R
mice as compared to wild-type controls (Figure 7c, d, f
and Figure 8c, d, f). These results indicate that the Fgfr2
+/P253R mutation contributes to the activation of p38
and ERK1/2 pathways in the skull.
Discussion
Similarities of the craniofacial phenotype of mice with
Fgfr2 P253R and S252W mutations
Mice carrying the heterozygous P253R mutation in the
Fgfr2 gene, and the heterozygous S252W mutant mice
that we reported previously [34], serve as models for
Apert syndrome as their phenotypes, especially the
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compared the two mutant inbred mice on the same
genetic background so that their phenotypes might
more clearly exhibit the differential effects of the muta-
tions without the added variation produced by varying
backgrounds. Standard cellular and molecular techni-
ques have been combined with precise 3D measures of
craniofacial anatomy captured by HRCT to provide non-
parametric statistical evaluation and qualitative compari-
sons of various aspects of the two models.
All surviving Fgfr2
+/P253R mice were small in size at
postnatal stages and had anomalies including abnormal
domed-shaped skulls with decreased rostro-caudal
length, increased height, and craniosynostosis. Synosto-
sis of the coronal suture was commonly present in the
mutant mice. These phenotypic features were in agree-
ment with those in previously reported Fgfr2
+/P253R mice
that were outbred and generated from TC1 ES cells
[35], which had a genetic background different from the
R1 ES cells used to create the mice reported here. In
Figure 6 Abnormal proliferation and differentiation at the chondro-osseous junction and metaphysis in Fgfr2
+/P253R mice. A, B) BrdU
staining shows increase in the numbers of proliferative cells in mutants at E19 (brackets). C-F) In situ hybridization of osteogenic markers shows
increased expression in mutants at P0: (C, D) osteopontin; (E, F) bone sialoprotein expression. Panels A, C and E are from littermate controls.
Panels B, D and F are the corresponding regions in mutant mice. (Scale bars: A-D = 50 μm).
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+/P253R mice, we noted additional abnormalities
in the neurocranium with premature fusions of zygo-
matic process of the maxilla and the zygomatic bones,
and fusion of the premaxillary-maxillary sutures. The
inter-premaxillary suture, on the other hand, was patent
at P0 in mutants and closed in the majority of wild-type
mice. This may indicate a localized delay in the fusion
of some sutures in Fgfr2
+/P253R mice. Similar results
were obtained for our Fgfr2
+/S252W mice [34].
The Fgfr2
+/P253R and Fgfr2
+/S252W mice showed most
of the characteristic skull features associated with Apert
syndrome (MIM #101200). For example, the coronal
suture closure, as presented in these mice, is the most
common skeletal phenotype in Apert syndrome patients
[24]. Furthermore, similar to humans with
Apert syndrome [39-41], the skulls of Fgfr2
+/P253R and
Fgfr2
+/S252W mice are typically brachycephalic, relatively
short along the anteroposterior axis and relatively wide.
In addition, the midfacial retrusion and maxillary hypo-
plasia described in humans with Apert syndrome[40,41]
also occurs in Apert mice as measured by statistically
significant reductions in all facial and palatal distances
in the mutant mice relative to their littermate controls.
Early fusion of the zygomatic-maxillary and the premax-
illa-maxillary sutures most likely contributes to the mid-
facial retrusion.
Differences in the craniofacial phenotype of mice with
Fgfr2 P253R and S252W mutations
Although the craniofacial phenotypes of the Fgfr2
+/P253R
and Fgfr2
+/S252W mice are generally similar, there were
differences in the craniofacial region between our sam-
ple of Fgfr2
+/P253R and the Fgfr2
+/S252W mice. Fgfr2
+/P253R mutant mice had less reduction of the maxilla
and therefore demonstrated less midface hypoplasia and
mandibular prognathism relative to Fgfr2
+/S252W mutant
mice. The Fgfr2
+/P253R mice also showed 50% less reduc-
tion of the total palate length compared to the affected
palates of Fgfr2
+/S252W mice. Further the suture between
the horizontal plate of the palatine bone and the palatal
shelf of the maxilla was patent in most of the Fgfr2
+/P253R mice and in at least half of the controls, but was
prematurely fused in most of the Fgfr2
+/S252W mice.
These results are generally consistent with human stu-
dies showing differences that have been characterized as
less severe craniofacial features in patients with the
Figure 7 Increased phosphorylated ERK1/2 and p38 and no change in phosphorylated PKCa and AKT in neurocranial tissues of Fgfr2
+/P253R at E17.5. A-D) Western blot analysis of different markers shows increased phosphorylated ERK1/2 and p38 and no change in
phosphorylated AKT and PKCa. E, F) Scatter plots using normalized levels of of mutant
phos/total/control
phos/total shows increased ratio of
phosphorylated ERK1/2 and p38 to total protein in the Fgfr2
+/P253R as compared to the wild-type neurocraniums. Each dot represents the analysis
of data from one embryo. The bar represents the median value.
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mutation [42,43]. Slaney et al. [42] analyzed 70 unre-
lated Apert syndrome patients with 25 having the
P253R mutation and 45 with the S252W mutation and
found that cleft palates were significantly less common
in patients with the former mutation. They also quanti-
fied the severity of the craniofacial phenotype including
maxillary hypoplasia by using a five-point preoperative
severity score. The mean score was higher for the het-
erozygous S252W group than for the P253R group,
although this difference was not significant. Yet, they
found that all three very mildly affected patients had the
P253R mutation, whereas the two most severely affected
patients both had the S252W mutation. Von Gernet et
al. [43] studied 21 patients, six with the P253R mutation
and 15 with the S252W mutation. The craniofacial
appearance of their patients with the dominant P253R
mutation following surgery was better than those with
the S252W mutations who had more pronounced mid-
facial and dental findings. Park et al. [26] reported on
35 patients, nine with the P253R mutation and 26 with
the S252W mutation, and showed that the cleft palates
were less common among patient with the P253R muta-
tion, but no statistical significance was demonstrated for
other craniofacial features. The consistency of the cra-
niofacial phenotypic differences between these two
mutations in humans and mice suggest that the func-
tional effects of the two mutations are indeed different.
However, further morphological studies with larger sam-
ple sizes are needed to confirm these results.
Importantly, we found a few features including the
lengths of nasal region and the anterior cranial base that
were significantly more affected in the Fgfr2
+/P253R as
compared to Fgfr2
+/S252W mice. In a few cases of
patients with Apert syndrome, the nasal and cranial
base lengths were also noted to be reduced in radio-
graphs, but their mutations were not analyzed [44].
These results indicate that each mutation has differential
effects on certain anatomical structures resulting in
varying localized phenotypic differences between the
two mouse mutants rather than one mutation causing
generally more severe phenotypes. Differences in the
Figure 8 Increased phosphorylated ERK1/2 and p38 and no change in phosphorylated PKCa and AKT in skull base tissues of Fgfr2
+/P253R at E17.5. A-D) Western blot analysis of different markers shows increased phosphorylated ERK1/2 and p38 and no change in
phosphorylated AKT and PKCa. E, F) Scatter plots using normalized levels of of mutant
phos/total/control
phos/total shows increased ratio of
phosphorylated ERK1/2 and p38 to total protein in the Fgfr2
+/P253R as compared to the wild-type skull bases. Each dot represents the analysis of
data from one embryo. The bar represents the median value.
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between the two mutant mice may be due to specific
tissue origins or localized variations in expression of
FGF/FGFRs with autocrine signaling, their differential
binding to their receptors and activation.
Abnormal osteogenesis at the calvarial sutures and long
bones in Fgfr2 P253R and S252W mice
Previous studies of human calvaria suggested abnormal
proliferation and differentiation of osteoblasts causes
the Apert syndrome phenotype [30,31,45]. Some of
these studies focused on postnatal suture samples from
Apert syndrome patients with the P253R mutation.
Fragale et al. [31] observed that mutant osteoblasts
had a lower proliferation rate, high alkaline phospha-
tase activity, increased mineralization and expression
of noncollagenous matrix proteins. Baroni et al. [45]
found abnormal differentiation with osteocalcin mRNA
down-regulated and FGF2 secretion increased. Other
studies were performed from cells derived from
patients with the S252W mutation. Lomri et al. [30]
showed normal cell proliferation and increased differ-
entiation with elevated expression of alkaline phospha-
tase and type 1 collagen in calvaria cells derived from
Apert infants and fetuses. Abnormal apoptosis has also
been found in human osteoblasts with the FGFR2
S252W mutation [32]. Premature apoptosis of osteo-
blasts and osteocytes was found in the mutant com-
pared to normal fetal suture of a 26 week fetus. Some
of these findings are not consistent perhaps because of
differences of culture conditions and difficulty in
obtaining appropriate human samples from early
embryonic studies.
In our in vivo mouse models, we observed consistent
presynostosis or synostosis of the coronal sutures during
development in both our Fgfr2
+/P253R and Fgfr2
+/S252W
mice [present study and 34]. We found decreased prolif-
eration, increased osteoblastic differentiation, accelerated
bone formation and no obvious difference in apoptosis
in mutant coronal sutures at late embryonic stages as
compared to controls. At the osteogenic fronts, there
are different cell types which perform different pro-
cesses, our results showed that at the coronal suture,
the numbers of BrdU labeled, proliferating cells are
decreased, whereas the preosteoblasts marked by ALP
and Runx2 staining are increased in the mutants, indi-
cating the shift towards more advanced osteoblast differ-
entiation and imbalance between proliferation and
differentiation at E17.5 in the Fgfr2
P253R/+ suture. Chen
et al. [33] and Holmes et al. [36] studied the coronal
suture in the same Fgfr2
+/S252W mice model [33,36].
Chen observed increased apoptosis from P1 to P8, post-
natal stages. Because no significant changes in prolifera-
tion and differentiation were detected from E16.5 to
P18, they suggested that the increased cell death/apop-
tosis might account for the premature fusion of the cor-
onal sutures in the Fgfr2
+/S252W mice [33]. Holmes
reassessed coronal suture fusion in the same mouse
model, they found that at E16.5 apoptotic cells appeared
in the mutant coronal sutures, but were strictly limited
to sites of osteoid contact between the frontal and parie-
tal bones, but above this area they saw decreased prolif-
eration in a more extended region. They suggested that
apoptosis appeared to be a consequence rather than a
cause of sutural fusion in Fgfr
S252W/+ mice. Earlier at
E12.5 they also examined the proliferation, and found a
modest increase in the coronal suture. From E13.5 to
E14.5 ectopic proliferation was observed in the basal
area of the coronal suture, but not in the osteogenic
fronts above this. They further found that, as fusion
continues in the Fgfr2
S252W/+ osteogenic fronts in the
more apical area of the suture at E16.5, there is a signifi-
cant decrease in proliferation possibly secondary to
greater osteoblast maturation [36]. Yin et al. [35] studied
the coronal suture in their Fgfr2
+/P253R mice. They
showed increased osteoblast differentiation at late
embryonic stages E16.5 and 17.5, but cell proliferation
and apoptosis were not examined [35].
We suggest, by combining our findings and those in
the literature, that abnormal proliferation and differen-
tiation in the coronal suture occurs primarily during the
early embryonic stages and is followed by apoptosis at
late embryonic and postnatal stages in both mutants,
although there can be in vivo variation. We also found
that long bone development was affected by abnormal
osteogenesis at late embryonic stages in our two mouse
models. Yin et al. [35] and our group [34,46] had
observed abnormal chondrogenesis in the skeleton of
Fgfr2
+/P253R and Fgfr2
+/S252W mice, respectively. We con-
clude that during prenatal stages, abnormal proliferation
and increased differentiation of mesenchyme and the
osteoblast/chondrocyte lineages in the developing coro-
nal suture and limb are important in the mechanism
leading to postnatal synostosis at sutures with apoptosis
and to shortening of the limbs.
Our previously published study of Fgfr2
+/S252W mice
focused on the midline interfrontal defect and sagittal
sutures from E16.5 to P1 [34]. We found increased pro-
liferating cells and abnormal expression of the osteo-
genic markers. We did not find an obvious midline
interfrontal defect in the Fgfr2
+/P253R mice at P0 as indi-
cated by examination of micro-CT scan and histology,
but Yin et al. [35] found a patent posterior frontal
suture at P17. It is possible that this defect becomes
more apparent with age or different genetic back-
grounds. We found increased or abnormal cartilage for-
mation in the mutant sagittal suture in our Fgfr2
+/P253R
mice, as did Yin et al. for their Fgfr2
+/P253R mice [35]
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+/S252W mice [34]. These observations
further support the fact that both Fgfr2 +/P253R and
+/S252W mutations affect chondrogenesis in Apert syn-
drome [34]. Also notable is the dissimilarity in the
pathogenesis between the developing mutant midline
and coronal sutures, which may in part be caused by
alterations in ligand availability and signaling pathways
involved local to specific sutures of different tissue
origin.
Abnormal signaling in osteogenesis of the skull in mice
with Fgfr2 P253R mutation
Molecular studies using Apert mouse models [35-37]
found enhanced expression levels of phosphorylated
ERK1/2 in visceral tissues and increased level of phos-
phorylated AKT and p38 in calvarial tissues of Fgfr2
+/S252W mice. In Fgfr2
+/P253R mice, ERK1/2 was the only
activated pathway reported in the bone marrow cell cul-
tures from long bones. Given that calvarial sutures and
the cranial base have different bone ossification pro-
cesses of intramembranous or endochondral bone for-
mation, respectively, we investigated the signaling
pathways involved in the neurocranium and base and
compared these results with those published for the
bone marrow cells of the long bones from the Fgfr2
+/P253R mice. Our studies showed increased phosphoryla-
tion of ERK1/2 and p38 in the skull, particularly in the
neurocranium of the Fgfr2
+/P253R mice. These results
indicate that in both intramembranous and endochon-
dral bone ossification in Apert syndrome, the activation
of MAPK pathways, in particular p38, may play an
important role in the abnormal proliferation and differ-
entiation in craniosynostosis of Fgfr2
+/P253R mice. Yin et
al. [35] revealed that inhibition of ERK1/2 activity partly
prevented the premature closure of coronal sutures and
recovered the retarded endochondral ossification of cul-
t u r e dm u t a n tf e m u r s .T h e ys p e c u l a t e dt h a ts o m eo t h e r
pathways may also be involved in the pathogenesis of
the skeleton phenotypes resulting from the Fgfr2 muta-
tion. Based on the consistent finding of activation of the
p38 pathway in calvarial tissues of our Fgfr2
+/P253R mice
and in Fgfr2
+/S252W mice[36], we propose that the p38,
as well as ERK1/2 pathways are involved in the patho-
genesis of skeletal abnormalities induced by the Fgfr2
P253R mutation.
Insights into the molecular mechanisms underlying
craniosynostosis models
The cellular mechanisms underlying craniosynostosis
have been investigated using other mouse models
[47,48]. For example, there are transgenic mice with
different mutations including Twist1
+/- [49], Fgfr1
P250R/+
[50], Fgfr2-IIIc
+/Δ [51], Fgfr2
C342Y/+ [52], Fgfr2
+/S252W
[33,34], Fgfr2
+/P253R [35], Axin2
-/- [53], Fgfr3
P244R [54];
and EphA4
-/- mice [55,56]. Analysis of these mice has
contributed insights into cranial suture biology and
mechanisms of craniosynostosis. FGF/FGFR signaling
has an important role in normal suture development
and craniosynostosis [48,50,57-59]. Twist1 mutant mice
exhibit coronal synostosis and mimic features of
Saethre-Chotzen syndrome [49,60]. It has been shown
that Twist1 regulates levels of FGFR2 expression and
phosphorylated ERK1/2 activity in sutures at late
embryonic and postnatal stages of mice [18,61]. Ephrin-
Eph signaling has important function in boundary for-
mation and the pathogenesis of coronal synostosis
[55,56]. EphA4, a receptor for ephrin-A2 and ephrin-A4
ligands, was detected on the ectocranial side of the pro-
spective frontal bone [55]. EphA4
-/- mice present defects
in the coronal suture and neural crest-mesoderm
boundary that phenocopy those of Twist1
+/- mice. It has
been shown that EphA4 is a Twist1 effector in coronal
suture development [56]. As downstream molecular sig-
nals of Twist1, both Fgfr2 and EphA4 function through
the RTK pathways to cause synostosis [61,56]. This may
explain why Fgfr2
+/P253R mice in our study and EphA4
mutant mice in the study of Ting et al. [56], both exhi-
bit enhanced expression of the early osteoblast markers
ALP and Runx2 within the synostosed suture, as well as
altered MAPK signaling. We hypothesize that ephrin/
Eph and Fgf/Fgfr signaling may converge to a common
mechanism involved in the development of craniosyno-
tosis and this hypothesis needs to be further studied.
Conclusion
There is in vivo v a r i a t i o ni np h e n o t y p i ca n dm o l e c u l a r
findings in Apert syndrome resulting from different
mutations, as well as possible differences in autocrine
FGF signaling, environmental factors and stochastic
events. Inbred mutant mouse models provide insight
into the pathogenesis of this condition. Our findings are
consistent in both Fgfr2
+/P253Rand Fgfr2
+/S252W mice for
the shortening of skull length, the presence of coronal
suture synostosis, and abnormal proliferation and differ-
entiation in the prenatal and newborn coronal suture
and long bones. We observed in the Fgfr2
+/P253R neuro-
cranium an increase in phosphorylated p38 as well as
ERK1/2, whereas phosphorylated AKT and PKCa were
not obviously changed as compared to those of wild-
type controls. Our results suggest a potential application
of combined modulators of the MAP kinases in the
treatment of craniosynostosis syndrome.
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Generation of targeting construct and mutant mice
The same 6.3 kilobase (kb) Hind III/Hind III fragment
containing exons 7-10 of murine Fgfr2 subcloned into
pBluescript II SK(-) used in this present study was pre-
viously described [34]. The 758C>G substitution, result-
ing in a P253R mutation at the residue homologous to
human FGFR2 amino acid 253, was introduced into
exon IIIa (exon 7) using site-directed mutagenesis. The
final targeting vector of 13.6 kb was confirmed by
sequencing, linearized by Not I digestion, and intro-
duced into R1 ES cells by electroporation (The Jackson
Laboratory). Positive cell clones were screened by
Southern blot analysis using Sty I digestion with 5’
probe and Sac I digestion with 3’ probe. Male chimeras
were generated and crossed with C57BL/6J females to
achieve germline transmission of the mutant allele. The
offspring were mated to generation N10 on the C57BL/
6J background. Heterozygotes with neo (+/P253Rneo)
were mated with EIIA promoter Cre transgenic mice
(EIIA-Cre, The Jackson Laboratory) to remove the neo
cassette. We maintained the previously reported Fgfr2
+/S252Wneo mice [34] from generation N10 on the
C57BL/6J background and mated it with the same EIIA-
Cre mice. Care and use of mice for this study were in
compliance with relevant animal welfare guidelines
approved by the Johns Hopkins School of Medicine and
Mount Sinai School of Medicine Animal Care and Use
Committee.
Mutant allele genotyping and RT-PCR expression analysis
Tail DNA were isolated by DNeasy tissue kit (Qiagen).
The genotypes were determined by PCR analysis using
primers from within Fgfr2 exon IIIa (forward primer F,
5’-TGCCTTTCTCCATCAGAAC-3’), intron IIIa
(reverse primer R, 5’-CAACAGGAAATCAAAGACC-3’)
and the neo cassette (forward primer Fn, 5’-CTGCAC-
GAGACTGAGAC-3’). Mice were sacrificed by inhala-
tion anesthetic overdose and necropsy was performed to
isolate RNA from various organs and tissues. Total RNA
was obtained by using the RNeasy® Mini Kit and cDNA
was synthesized by Omniscript RT Kit (Qiagen). Fgfr2
RNA expression was detected using primers correspond-
ing to the Fgfr2 coding sequence of exons 5 and 10 (for-
ward primer 5’-CAACACCGAGAAGATGGAG-3’ and
reverse primer, 5’-CCATGCAGGCGATTAAGAAG-3’).
The PCR products were digested with BstE II to distin-
guish the wild-type from the mutant P253R allele.
Skeletal staining, measurements, and histological analysis
Skeletal staining with Alizarin red S and Alcian blue was
performed [62]. Gross limb measurements including the
length of the humerus, radius ,u l n a ,f e m u r ,t i b i a ,a n d
fibula were taken with digital calipers on adult skeletons
(Fisher Scientific). Whole heads and femurs of embryos
at E14.5 to P10 were dissected. Histological sections (5
μm) were prepared from selected tissues that had been
fixed in 4% paraformaldehyde for 24-48 hours and
embedded in paraffin. Sections were stained with hae-
matoxylin and eosin (HE) for histology.
The planes of the histological sections are described
below. We studied the transverse coronal and lambdoid
sutures by sectioning the head with a sagittal plane
using the anterior-posterior axis from the nose to verte-
bra. The sections analyzed were selected from the mid-
dle third portion of the unilateral coronal or unilateral
lambdoid suture. We studied the vertical sagittal suture
by sectioning the head with a coronal plane. The sec-
tions analyzed were selected from the middle third por-
tion of the sagittal suture.
High resolution micro-CT image acquisition and landmark
data analysis
P0 mice were sacrificed and fixed in 4% paraformalde-
hyde. High resolution micro-computed tomography
(HRCT) images of all skulls were acquired at the Center
for Quantitative Imaging at Pennsylvania State Univer-
sity http://www.cqi.psu.edu using an OMNI-X Universal
HD600 industrial x-ray high resolution computed tomo-
graphy system (Bio-Imaging Research Inc., Lincolnshire
IL). Images of 37 mice were acquired in the coronal
plane with slice thicknesses of 24.9 microns (z dimen-
sion) and pixel sizes of 20 microns (x and y dimen-
sions). Image data were reconstructed on a 1024 × 1024
pixel grid as 16 bit TIFF but reduced to 8 bit for image
analysis. Three-dimensional coordinate locations of 32
biologically relevant cranial landmarks were recorded
for all of the mice using eTDIPS, 3D reconstruction and
visualization software for medical images http://www.cc.
nih.gov/cip/software/etdips/. Detailed descriptions of
these landmarks are provided on the landmark collec-
tion page at the Richtsmeier laboratory website http://
www.getahead.psu.edu/landmarks_new.html. Previous
analyses by our lab have demonstrated the accuracy and
precision of this data collection method for CT scans
[63,64]. To minimize measurement error, two data col-
lection trials were completed for the images of each spe-
cimen and the averages of those trials were used for
analyses.
Differences in skull shape were evaluated using the
3D landmark coordinate data and Euclidean Distance
Matrix Analysis or EDMA [65] that converts 3D land-
mark data into a matrix of all possible linear distances
between unique landmark pairs. For each sample, an
average form is estimated using the linear distance data
and differences in three-dimensional size and shape are
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ear distances in the two samples. For our study, three
statistical comparisons of shape and size were com-
pleted. The first two comparisons assessed the intra-
model differences, comparing mutant mice within each
model with their normal littermates, that is Fgfr2
+/P253R
mice with normal littermates and Fgfr2
+/S252W mice
with normal littermates. The third comparison evalu-
ated inter-model differences obtained in the two intra
model comparisons. This was accomplished by statisti-
cally comparing Fgfr2
+/P253R -with-wild-type littermate
contrasts to Fgfr2
+/S252W -with- wild-type littermate
contrasts using already established methods [65]. The
null hypothesis for each comparison is that there is no
difference in shape between groups (or no difference in
shape contrasts). For each linear distance, a ratio
between the average value of that distance in each
group is computed. A value of 1 indicates that the two
groups are similar for that measure; whereas a value sig-
nificantly greater or less than 1 shows that they are dif-
ferent. Confidence intervals for the null hypothesis of
similarity in shape are estimated from 100,000 pseudo-
samples generated from the data using a non-parametric
bootstrapping algorithm. For each linear distance the
null hypothesis is rejected if the 90% confidence interval
produced from the bootstrapping method does not
include 1.0. Rejection of the null hypothesis enables
localization of differences to specific landmarks and lin-
ear distances.
Immunohistochemical, TUNEL, and alkaline phosphatase
(ALP) assays
For 5-bromo-2’-deoxyuridine (BrdU) labeling, pregnant
mice were injected with a 10 mg/ml solution of BrdU
(Sigma) at 100 μg/g body weight 2 hours before sacri-
fice. Skull sutures and long bones, sectioned as above,
were deparaffinized with xylene and rehydrated through
a graded alcohol series. The immunohistochemical
assays for BrdU were performed using the BrdU In-Situ
Detection Kit (BD Biosciences) and VECTOR M.O.M
Immunodetection Kit (Vector Laboratories). The sec-
tions were counterstained with hematoxylin. Cell prolif-
eration was analyzed by counting the number of BrdU-
positive cells to total cells with hematoxylin-stained
nuclei in a defined area, including the osteogenic fronts
and intervening sutural mesenchyme from four mutant
and four littermate controls of at least two litters. The
ratios in mutant and wild-type embryos were compared
by Wilcoxon test. Immunohistochemical staining for
Runx2 was performed using rabbit anti-Runx2 antibody
(Sigma). The TUNEL assay was done using the In Situ
Cell Death Detection Kit, POD (Roche Applied Science)
to detect apoptotic cell death by light microscopy. ALP
staining was carried out as described [34]. Alkaline
phosphatase in skull sutures and growth plates were
stained using the TRACP and ALP double-stain kit
(TaKaRa Bio).
In situ hybridization
In situ hybridization was performed on sections as
described by Wilkinson [66] with modifications. The
mouse osteonectin, osteopontin, type I collagen, and
osteocalcin cDNA fragments were each cloned into the
pCR® II-TOPO® Vector. The plasmids were linearized
and antisense and sense single-stranded RNA probes
were generated using T7, T3 or SP6 RNA polymerase
with digoxigenin (Roche).
Protein preparation and western blotting
Calvaria skull and skull base were separately isolated by
microdissection from E17.5 embryos from at least three
different litters of each mutant Fgfr2
+/P253R and Fgfr2
+/S252W. These tissue samples were homogenized in T-
PER
R Tissue Protein Extraction Reagent (Thermo Scien-
tific) using a pellet pestle motor homogenizer (Kontes).
Protein concentration was determined with Pre-Diluted
Protein Assay Reagent (Pierce). Freshly isolated protein
was loaded in equal amounts and resolved on a 4-15%
SDS-PAGE gel. Proteins were electrotransferred to
PVDF membrane (Biorad), incubated with the specific
antibodies, and were visualized by ECL Plus Western
Blotting Detection System (Amersham). To assure con-
sistency in technique, western blot analysis was per-
formed independently at least twice for each protein
sample. The antibodies used were against Fgfr2 (SC-122;
Santa Cruz); phospho-ERK1/2 (#9101, Cell Signaling
Technology), total ERK (#9102), phospho-AKT (#9217),
total AKT (#9272), phospho-p38 (#9211), total p38
(#9212), phospho-PKCa (#9375, Cell Signaling Technol-
ogy), total PKCa (#610107, BD Transduction Labora-
tories™); and b-actin (Sigma). The levels of protein
expression were quantified using the Alpha Innotech
Image Analysis System and normalized relative to the
expression of the control, b-actin. The comparison of
protein levels were calculated by taking a ratio of the
normalized phosphorylated protein level to total protein
level of the mutant to wild-type. To compare the med-
ian phosphorylation ratio of mutant samples to wild-
type (ratio = 1), the one-sample Wilcoxon test was used.
Statistical significance was assigned at P < 0.05. All sta-
tistical analyses were performed using SAS/STAT soft-
ware (SAS Institute, Inc., Cary, NC). The scatter plots
were generated by GraphPad Prism 5 http://www.graph-
pad.com/prism/Prism.htm.
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Page 17 of 20Additional file 1: Generation of Fgfr2 P253R mutation in mice. A)
Targeting construct created with a TK cassette, neo cassette with flanking
loxP sequences, and a portion of the wild-type Fgfr2 gene (including
exons IIIa, IIIb, and IIIc, but not exon 10) introduced by Hind III (H)
digestion; mutant allele produced by homologous recombination and
neo deletion mediated by Cre. The 758C>G, P253R mutation (*) was
introduced into exon IIIa. Probes (-) and restriction enzyme Sty I (St) or
Sac I (S) used for Southern blot analysis and PCR primers (F, Fn, R arrows)
for genotyping are shown. B) Identification of mutant and wild-type
alleles in ES cell clones using Southern-blot analysis with 5’- and 3’-
probes. The mutant allele shows 4.1 kb and 8.3 kb bands with the 5’-and
3’-probes, respectively. C) Genotyping results from PCR of tail DNAs. Lane
1: 100 bp DNA ladder; lane 2: wild-type +/+, 290 bp; lane 3:
heterozygote with +/P253R
neo [wild-type allele and P253R allele with neo
casette, 400 bp]; and lane 4: heterozygote mutant +/P253R [wild-type
allele and mutant allele after neo deletion with only one remaining loxP
sequence, 350 bp].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-
22-S1.PDF]
Additional file 2: Fgfr2 P253R mutant mice. A, B) Fgfr2 mRNA and
protein expression in skull tissue. (A) RT-PCR of Fgfr2. Lane 1: 100 bp
DNA ladder; lane 2: wild-type +/+ transcript, 700 bp digested with BstE II
into 410 bp and 290 bp fragments; lane 3: heterozygote P253R
neo 700
bp mutant allele can not be digested with BstE II and is expressed
weakly as compared with the digested wild-type alleles; and lane 4:
heterozygote +/P253R 700 bp mutant and wild-type alleles with similar
expression. (B) Western blot of Fgfr2 protein expression. Lane 1: wild-type
+/+; and lane 2: heterozygote +/P253R with similar expression as wild-
type. Levels of expression are normalized to the ratio of Fgfr2 to b-actin
expression of the wild-type +/+. C, D) Gross appearance of Fgfr2
+/P253R
mice. (C) Note no significant difference in the body size and limb length
(arrowheads) between the wild-type and mutant at P0. The mutant has a
dome-shaped skull (arrow). (D) Note significant difference in the body
size between the wild-type and mutant at P10. E, F) Weight and survival
curves of Fgfr2
+/P253R (pink) and wild-type (blue) mice. (E) Weights of
mice with age showing growth retardation in the mutant. (F) Survival
curves showing most mutants died within 2 weeks of birth.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-
22-S2.PDF]
Additional file 3: Abnormal proliferation, differentiation and no
obvious change in apoptosis at the coronal suture in Fgfr2
+/S252W
mice. A, B) Immunohistochemical staining of BrdU shows decreased
numbers and abnormal distribution of positive cells in mutants at E17.5
(arrow). C, D) ALP staining showed broad ALP domain and expansion of
expression into the coronal suture of the mutants at E17.5 (arrow). E, F)
In situ hybridization of osteonectin shows accelebrated bone formation
in mutants at P0. G, H) TUNEL staining shows no clear difference in
apoptosis between the mutant and wild-type at P0 (arrows). Panels A, C,
E and G are from littermate controls. Panels B, D, F and H are the
corresponding regions in mutant mice. (Scale bars: A-F = 50 μm).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-
22-S3.PDF]
Additional file 4: Abnormal proliferation and differentiation at the
chondro-osseous junction and metaphysis in Fgfr2
+/S252W mice. A, B)
BrdU staining shows increase in the numbers of proliferative cells in
mutants at E17.5 (brackets). C-F) In situ hybridization of osteogenic
markers shows increased expression in mutants at P0: (C, D) osteopontin;
(E, F) bone sialoprotein expression. Panels A, C and E are from littermate
controls. Panels B, D and F are the corresponding regions in mutant
mice. (Scale bars: A-D = 50 μm).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-
22-S4.PDF]
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